Trial Profile

A Phase 1, Single Center Study to Assess the Safety of MB66, a Combined Anti-HIV (VRC01-N) and Anti-HSV (HSV8-N) Monoclonal Antibody Film for Vaginal Application as Microbicide

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MB 66 (Primary)
Indications Herpes simplex virus infections; HIV infections
Focus Adverse reactions
Acronyms VAST
Sponsors Leaf Biopharmaceutical

Most Recent Events

11 Mar 2020 Results (n=29) assessing safety and tolerability of MB66 film, presented at the 27th Conference on Retroviruses and Opportunistic Infections.
17 Dec 2018 Status changed from recruiting to completed.
07 Mar 2018 Results (n=8) assessing women safety and antiviral effects (ex vivo) of MB66 film antibodies when delivered vaginally, were presented at the 25th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com